A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON) in subjects with Parkinson's Disease
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Apomorphine (Primary) ; Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 27 Nov 2022 Status changed from recruiting to discontinued.
- 03 Dec 2020 New trial record